Avacta’s pre|CISION platform wins UK pharma R&D award

London and Philadelphia - Avacta Group, a developer of targeted oncology drugs, announced that its pre|CISION platform has earned the Research and Development Achievement Award from the Pharma Industry Awards UK 2026. The award, according to a press release, recognizes significant research and development milestones achieved within the past year.

The pre|CISION platform is engineered to transport anticancer agents directly to tumors, while minimizing harm to healthy tissues. Avacta's initial candidate utilizing this platform, AVA6103, has commenced clinical trials under the FOCUS-01 study. Christina Coughlin, Avacta's CEO, highlighted the company's remarkable ability to bring AVA6103 into the clinical phase at an unprecedented pace.

Recent clinical data on AVA6103 demonstrates the effectiveness of this mechanism, and Avacta is eagerly anticipating ongoing updates and progress on the entire pipeline. Currently, the company is actively recruiting patients for the AVA6103 FOCUS-01 trial. This news piece was produced with the assistance of artificial intelligence and subsequently reviewed by a human editor. For additional information, please refer to the Terms and Conditions.